IMRX - Immuneering GAAP EPS of -$0.49 in-line revenue of $38.38M
- Immuneering press release ( NASDAQ: IMRX ): Q3 GAAP EPS of -$0.49 in-line.
- Revenue of $38.38M (-92.0% Y/Y).
- Cash and cash equivalents and marketable securities as of September 30, 2022, were $117.2 million, compared with $150.2 million as of December 31, 2021.
For further details see:
Immuneering GAAP EPS of -$0.49 in-line, revenue of $38.38M